Curis is a biotechnology company focused on the development
and commercialization of innovative drug candidates for the treatment of human
cancers. The company’s leading product candidate, CUDC-907, is currently in
phase I clinical trials for the treatment of lymphoma and multiple myeloma, as
well as solid tumors. Additionally, the company’s product pipeline includes
CUDC-427, which is being studied for the treatment of solid tumors and
lymphomas, and CUDC-305 for the treatment of cancers.
The company’s most advanced drug, Erivedge®, was developed
in collaboration with Genentech, Inc. and is currently approved for use in
patients with advanced basal cell carcinoma (BCC) in the United States, the
European Union, Australia and a collection of other countries. The potential
market for Erivedge is extensive. According to a report by the Skin Cancer
Foundation, an estimated 2.8 million patients in the U.S. are diagnosed with
BCC annually, making it the most common form of skin cancer. In the first quarter
of 2015, Curis recorded $1.7 million in royalty revenues from global sales of
the product, representing a 30 percent year-over-year improvement.
In recent months, Curis has made significant progress toward
the continued expansion of its promising product pipeline. In January, the
company entered into an exclusive collaboration agreement with Aurigene
Discovery Technologies Limited focused on the discovery, development and
commercialization of small molecule immuno-oncology therapeutics. In the months
to come, Curis will have the option to exercise exclusive licensing rights on a
selection of drug candidates already in clinical development, providing a
platform for strong financial growth.
With an established and growing presence in the
immuno-oncology treatment industry, Curis has access to near limitless market
potential moving forward. According to investment bank Leerink Swann, the
immuno-oncology market is expected to reach a value of approximately $29
billion within the next decade, potentially revolutionizing the treatment
options for a wide variety of cancer types along the way.
For prospective investors, Curis’s recent clinical progress
could foreshadow an opportunity for improved returns in the coming years. Look
for the company to leverage the expanding demand for innovative immuno-oncology
treatment options in order to promote continued market growth in the future.
For more information, visit www.curis.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
